Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug
Reports submitted to regulators have raised concern, but they do not establish that the medicine caused the events.
TL;DR
- STAT reported that seven deaths and nearly 100 hospitalizations had been reported among people prescribed Vykat XR since its approval.
- The adverse-event reports do not prove causation, and the patients had complex medical conditions and sometimes used other medications.
- Patient advocates and some experts are pressing for scrutiny while others urge caution; no new regulatory action was confirmed in the reporting.
STAT reported that case reports submitted to regulators included seven deaths and nearly 100 hospitalizations among people prescribed Neurocrine Biosciences’ Vykat XR since its approval. The reports concern a treatment for hyperphagia in people with Prader-Willi syndrome. [1]
The outlet obtained the case reports through a Freedom of Information Act request. It emphasized that the reports do not establish causality: many cases involved complex medical conditions and multiple medications. [1]
The Prader-Willi Syndrome Association’s safety page also describes reports in the FDA adverse-event system and says the available reports cannot determine whether the drug caused the events. Some advocates and experts want more scrutiny, while other clinicians urge careful interpretation. [2]
The open questions include whether further investigation will identify a causal link and whether regulators or the manufacturer will change monitoring or labeling. The current reports are a safety signal for review, not proof of a drug effect and not a basis for individual treatment advice. [1]
Why it matters
The reports show how post-market safety signals can trigger scrutiny for a rare-disease medicine, but spontaneous reports cannot establish causation or quantify individual risk.
Editor's note
Reported adverse events do not establish causality; no medical advice is offered.